Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a proof-of-mechanism study of AMG 557/MEDI5872 in primary Sjogren's syndrome
2014-003896-41Phase 2Completed
- Sponsor
- MedImmune
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome (SS) comparing AMG 557/MEDI5872 with Placebo (2 arms). Primary endpoint: Change in ESSDAI score from baseline to Day 99. Started Feb 2015; status: completed.
02
Drugs
prezalumab
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on 2014-003896-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003896-41.